Literature DB >> 30787168

Challenges for mesenchymal stromal cell therapies.

Ivan Martin1, Jacques Galipeau2, Charles Kessler3, Katarina Le Blanc4, Francesco Dazzi5.   

Abstract

Clinical trials of mesenchymal stromal cell therapies reveal a challenging heterogeneous landscape, including diverse therapeutic targets, patient categories, cell sources, and potential mechanisms of action.
Copyright © 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Entities:  

Mesh：

Year:  2019        PMID： 30787168     DOI： 10.1126/scitranslmed.aat2189

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN： 1946-6234            Impact factor:   17.956


  58 in total

Review 1.  Frustrated differentiation of mesenchymal stem cells.

Authors:  Satoru Kidoaki
Journal:  Biophys Rev       Date:  2019-05-17

2.  Therapeutic implications of transplanted-cell death.

Authors:  Zachary W Wagoner; Weian Zhao
Journal:  Nat Biomed Eng       Date:  2021-05       Impact factor: 25.671

Review 3.  Advances in translational orthopaedic research with species-specific multipotent mesenchymal stromal cells derived from the umbilical cord.

Authors:  Melina Ramallo; Irene Carreras-Sánchez; Alba López-Fernández; Roberto Vélez; Màrius Aguirre; Sara Feldman; Joaquim Vives
Journal:  Histol Histopathol       Date:  2020-09-11       Impact factor: 2.303

Review 4.  Stem cell therapy for muscular dystrophies.

Authors:  Stefano Biressi; Antonio Filareto; Thomas A Rando
Journal:  J Clin Invest       Date:  2020-11-02       Impact factor: 14.808

Review 5.  Mesenchymal Stem/Progenitor Cells: The Prospect of Human Clinical Translation.

Authors:  Dina Rady; Marwa M S Abbass; Aiah A El-Rashidy; Sara El Moshy; Israa Ahmed Radwan; Christof E Dörfer; Karim M Fawzy El-Sayed
Journal:  Stem Cells Int       Date:  2020-08-11       Impact factor: 5.443

6.  Human Fallopian Tube - Derived Mesenchymal Stem Cells Inhibit Experimental Autoimmune Encephalomyelitis by Suppressing Th1/Th17 Activation and Migration to Central Nervous System.

Authors:  Carla Longo de Freitas; Carolina Manganeli Polonio; Wesley Nogueira Brandão; Cristiano Rossato; Nágela Ghabdan Zanluqui; Lilian Gomes de Oliveira; Marília Garcia de Oliveira; Lucila Pires Evangelista; Silvio Halpern; Mariangela Maluf; Carlos Eduardo Czresnia; Paulo Perin; Danilo Candido de Almeida; Jean Pierre Schatzmman Peron
Journal:  Stem Cell Rev Rep       Date:  2021-08-28       Impact factor: 5.739

7.  Use of MSCs and MSC-educated macrophages to mitigate hematopoietic acute radiation syndrome.

Authors:  Raghavan Chinnadurai; Matthew H Forsberg; John A Kink; Peiman Hematti; Christian M Capitini
Journal:  Curr Stem Cell Rep       Date:  2020-08-08

Review 8.  Stem Cell Therapies for Progressive Multiple Sclerosis.

Authors:  Jayden A Smith; Alexandra M Nicaise; Rosana-Bristena Ionescu; Regan Hamel; Luca Peruzzotti-Jametti; Stefano Pluchino
Journal:  Front Cell Dev Biol       Date:  2021-07-09

Review 9.  Considerations in the Design of Non-Clinical Development Programmes to Support Non-Viral Genetically Modified Mesenchymal Stromal Cell Therapies.

Authors:  Valeria Iansante; Andrew Brooks; Lee Coney
Journal:  Pharmaceutics       Date:  2021-06-02       Impact factor: 6.321

Review 10.  Characterisation of mesenchymal stromal cells in clinical trial reports: analysis of published descriptors.

Authors:  Alison J Wilson; Emma Rand; Andrew J Webster; Paul G Genever
Journal:  Stem Cell Res Ther       Date:  2021-06-22       Impact factor: 6.832
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.